ALLMedicine™ Lipoprotein (a) Center

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

Jan 9th, 2021 - Elevated plasma lipoprotein (a) [Lp(a)] and coronary artery calcification (CAC) are established cardiovascular risk factors that correlate with each other. We hypothesized that other cardiovascular risk factors could affect their relationship. We ...

Jan 2nd, 2021 - Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in pat...

Dec 14th, 2020 - Lipoprotein (a) [Lp(a)] has been considered a determinant of residual cardiovascular risk. We aimed to investigate associations between serum Lp(a) levels and carotid atherosclerosis. This cross-sectional study included 662 type 2 diabetic patient...

Feb 24th, 2021 - To investigate the population attributable fraction due to elevated lipoprotein (a) (Lp(a)) and the utility of measuring Lp(a) in cardiovascular disease (CVD) risk prediction. In 413 734 participants from UK Biobank, associations of serum Lp(a) wi...

Feb 21st, 2021 - The management of heterozygous familial hypercholesterolaemia with high lipoprotein (a) and statin intolerance. The guidelines a mirage?|2021|Dal Pino B,Bigazzi F,Sbrana F,Sampietro T,|

Jan 9th, 2021 - Elevated plasma lipoprotein (a) [Lp(a)] and coronary artery calcification (CAC) are established cardiovascular risk factors that correlate with each other. We hypothesized that other cardiovascular risk factors could affect their relationship. We ...

Jan 2nd, 2021 - Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] levels in pat...

Dec 14th, 2020 - Lipoprotein (a) [Lp(a)] has been considered a determinant of residual cardiovascular risk. We aimed to investigate associations between serum Lp(a) levels and carotid atherosclerosis. This cross-sectional study included 662 type 2 diabetic patient...

Feb 25th, 2019 - ZURICH (Reuters) - Novartis will pay $150 million to Ionis Pharmaceuticals to license an RNA-targeting cardiovascular drug as the Swiss company aims to bolster its range of heart disease treatments that now includes the blockbuster Entresto. FILE ...

May 1st, 2014 - Randomized controlled trials have unequivocally shown that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces the rate of cardiovascular events. 1–3 Yet many patients still have heart attacks even though they are on.

Feb 5th, 2013 - MONTREAL, Quebec — An international consortium has identified a variation in the gene coding for lipoprotein (a) (Lp[a]), which appears to be strongly associated with aortic-valve calcification [1]. People carrying this single nucleotide polymorph...

Nov 30th, 2011 - December 1, 2011 (Houston, Texas) — Elevated levels of lipoprotein (a) [Lp(a)] are associated with cardiovascular events in African Americans, and the risk is comparable to that seen in whites, a new analysis of the Atherosclerosis Risk in Communi...

Jul 20th, 2009 - July 21, 2009 (Cambridge, United Kingdom) — A new pooled analysis of 36 prospective studies shows there is a continuous association between blood concentration of lipoprotein (a)--Lp(a)--and the risk of MI and stroke [1]. Importantly, this associa...